Clinical trial
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 23, 2023
- Completion date
- August 17, 2026
- Enrollment
- 352 (actual)
- Sites
- 74
Conditions
As the registry lists them; a condition with its own page is linked.